SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021

Rhea-AI Summary

SELLAS Life Sciences Group (NASDAQ: SLS), a biopharmaceutical company focused on cancer immunotherapies, announced that CEO Angelos Stergiou will participate in two key conferences. The first is the Laguna Biotech CEO Forum from October 10-12, 2021, in Laguna Beach, CA. The second is the A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference on October 13, 2021, which will be held virtually. SELLAS aims to advance its immunotherapeutic candidates, galinpepimut-S and nelipepimut-S, targeting various cancer indications.

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences:

• Laguna Biotech CEO Forum 2021 to be held at the Montage Laguna Beach hotel in Laguna Beach, CA on October 10-12, 2021.
  
  
• A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference to be held virtually on Wednesday, October 13, 2021.
  

For more information about the conferences, or to schedule a one-on-one meeting with SELLAS management, please contact your representative directly, or send an email to A.G.P./Alliance Global Partners at agpevents@allianceg.com, or KCSA Strategic Communications at SELLAS@kcsa.com.

About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer (TNBC) patients, following the standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Investor Contacts
Allison Soss
KCSA Strategic Communications
212.896.1267
SELLAS@kcsa.com

Media Contacts
Raquel Cona
KCSA Strategic Communications
212.896.1204
SELLAS@kcsa.com

FAQ

When will SELLAS Life Sciences Group participate in the Laguna Biotech CEO Forum?

SELLAS Life Sciences Group will participate in the Laguna Biotech CEO Forum from October 10-12, 2021.

What is the focus of SELLAS Life Sciences Group?

SELLAS Life Sciences Group focuses on developing novel cancer immunotherapies.

What is the date of the A.G.P./Alliance Global Partners Biotech Conference?

The A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference will take place on October 13, 2021.

What are the lead product candidates of SELLAS Life Sciences Group?

SELLAS' lead product candidates are galinpepimut-S and nelipepimut-S, targeted at various cancer types.

Where can I find more information about SELLAS Life Sciences Group?

More information about SELLAS Life Sciences Group can be found on their website at www.sellaslifesciences.com.